Building roadblocks between transcription and translation
Isis Pharmaceuticals (ISIS) pioneers a drug development platform that targets specific mRNA strands, after transcription, and stops them from being translated into troublesome proteins. Despite its unfortunate name, antisense technology is an extremely good method for creating the sort of highly targeted compounds the FDA likes.
Through antisense based drug development, Isis has become a highly efficient drug discovery machine. It is so efficient that Isis couldn't possibly afford to test and market even a fraction of the compounds it creates, so it doesn't
In a nutshell, Isis's business model consists of it discovering and developing drugs, then letting the grown-ups do the dirty work. Isis has licensing agreements with AstraZeneca (NYSE:...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|